How to Source Pyrantel Pamoate chewable tablets for Pharmaceutical Formulation

Pyrantel Pamoate chewable tablets (Tablets, 11 mg) is classified under Anthelmintic. It is therapeutically aligned with reference brands such as Pin-X(US),Combantrin(EU). This guide highlights key sourcing factors buyers should consider when procuring high-quality Pyrantel Pamoate chewable tablets for formulation, R&D, or bulk manufacturing.

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Pyrantel Pamoate chewable tablets must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Pyrantel Pamoate chewable tablets is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Pyrantel Pamoate chewable tablets is more than procurement—it’s a strategic partnership. With its tablets form and 11 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions About Pyrantel Pamoate chewable tablets